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Longitudinal analysisGrey matter (GM) atrophy occurs early in primary progressive MS (PPMS), but it is unknown whether its pro-
gression involves different brain regions at different rates, as is seen in other neurodegenerative diseases. We
aimed to investigate the temporal and regional evolution of GM volume loss over 5 years and its relationship
with disability progression in early PPMS.
We studied 36 patientswith PPMSwithin ﬁve years fromonset and 19 age and gender-matched healthy controls
with clinical and imaging assessments at study entry and yearly for 3 years and then at 5 years. Patients were
scored on the expanded disability status scale (EDSS) and MS Functional Composite (MSFC) at each time-
point. An unbiased longitudinal voxel-based morphometry approach, based on high-dimensional spatial align-
ment within-subject, was applied to the serial imaging data. The rate of local (voxel-wise) volume change per
year was compared between groups and its relationship with clinical outcomes was assessed.
Patients deteriorated signiﬁcantly during the ﬁve years follow-up. Patients showed a greater decline of GM vol-
ume (pb0.05, FWE-corrected) bilaterally in the cingulate cortex, thalamus, putamen, precentral gyrus, insula and
cerebellumwhen compared to healthy controls over ﬁve years, although the rate of volume loss varied across the
brain, and was the fastest in the cingulate cortex. Signiﬁcant (pb0.05, FWE-corrected) volume loss was detected
in the left insula, left precuneus, and right cingulate cortex in patients at three years, as compared to baseline,
whilst the bilateral putamen and the left superior temporal gyrus showed volume loss at ﬁve years. In patients,
there was a relationship between a higher rate of volume loss in the bilateral cingulate cortex and greater clinical
disability, as measured by the MSFC, at ﬁve years (Pearson's r=0.49, p=0.003).
Longitudinal VBMdemonstrated that the progression of GMatrophy in PPMS occurs at different rates in different
regions across the brain. The involvement of the cingulate cortex occurs early in the disease course, continues at a
steady rate throughout the follow-up period and is associatedwith patient outcome. These ﬁndings provide new
insights into the characteristics of GM atrophy across the brain in MS, and have potential consequences for the
selection of brain atrophy as an outcome measure in neuroprotective clinical trials.
© 2013 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
It has recently been proposed thatmultiple sclerosis (MS) is primar-
ily a neurodegenerative rather than an autoimmune disease (Stys et al.,
2012). In primary progressive MS (PPMS), the neurodegenerativeerms of the Creative Commons
tribution, and reproduction in
credited.
Square MS Centre, UCL Institute
lished by Elsevier Inc. All rights reserelement is prominent and the secondary inﬂammatory reaction is less
evident than in the relapse-onset forms (Stys et al., 2012). This
neurodegenerative component leads to macroscopic brain atrophy,
which may be captured in vivo by brain imaging, providing a potential
outcome measure for clinical trials (Barkhof et al., 2012). Grey matter
(GM) atrophy is greater in secondary-progressive MS than in relaps-
ing–remitting disease (Miller et al., 2012; Roosendaal et al., 2011) and
is an independent predictor of physical and cognitive disability in MS
(Calabrese et al., 2013). Additionally, in secondary progressive MS, the
loss of volume of GM is greater than that seen in the white matter
(WM) (Kapoor et al., 2010) and it shows a more robust relationship
with disability than visible WM lesions (Miller et al., 2012).ved.
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ferent subtypes of MS (Battaglini et al., 2009; Bendfeldt et al., 2012;
Ceccarelli et al., 2008; Fisher et al., 2008; Khaleeli et al., 2007), the
patterns of dynamic changes in GM over time and their relationship
with clinical disability in MS are not well-deﬁned. In a cohort of pa-
tients with early PPMS, we used cross-sectional voxel-based mor-
phometry and found that GM atrophy is localized at study entry to
speciﬁc regions, such as the thalamus and the pre- and post-
central gyri (Khaleeli et al., 2007); volume loss in the bilateral thal-
ami, cortical and infratentorial regions was detected during one year
follow-up with the same methodology (Sepulcre et al., 2006). How-
ever, in PPMS it is not known if the progression of GM atrophy over a
longer follow-up involves different brain regions at different stages
or with different rates, as is seen in other neurodegenerative condi-
tions, such as Alzheimer's disease (Chetelat et al., 2005) and
Huntington's disease (Hobbs et al., 2010).
To investigate the temporal and regional behaviour of GM atrophy
over time, it is important to employ the latest techniques that can esti-
mate and localise GM volume changes across all the available time-
points, rather than calculating the GM volume independently at each
follow-up visit. Additionally, it is preferable not to use the baseline scan
as the reference scan in the analysis of longitudinal volume changes, as
this can bias the results (Reuter and Fischl, 2011; Yushkevich et al.,
2010). These new techniques, called tensor-based morphometry (TBM)
and longitudinal voxel-based morphometry (VBM), are considered to
be more precise than standard VBMmethods (i.e., less variable and less
prone to outliers) (Anderson et al., 2012), and have been used success-
fully in other diseases, such as Huntington's disease (Kipps et al., 2005),
frontotemporal dementia (Brambati et al., 2007), and Alzheimer's dis-
ease (Hua et al., 2008). The application of TBM to MS has been limited
to cross-sectional studies (Aubert-Broche et al., 2011).
In this study, we employed a novel longitudinal VBM approach to
describe the temporal and regional evolution of GM volume loss in
early PPMS during a ﬁve-year follow-up. Additionally, we aimed to in-
vestigate the relationship between temporal GM volume changes and
clinical outcome.Materials and methods
Subjects
Thirty-six patients with PPMS diagnosed according to Thompson's
criteria (Thompson et al., 2000), within 5 years of symptom onset, and
19 age and gender-matched healthy volunteers, were investigated
(see Table 1 for demographic and disease characteristics). These pa-
tients were a subgroup of the original cohort of PPMS patients who
underwent at least one follow-up scan (Khaleeli et al., 2007); eightTable 1
Demographic and disease characteristics at baseline for patients and healthy controls.
Patients, N=36 Controls, N=19 Signiﬁcance
Mean age, (CIa 95%) 42.8 (39.4, 46.6) 37.6 (33.4, 41.9) NSb
Gender NS
Female, N (%) 12 (33%) 9 (47%)
Male, N (%) 24 (67%) 10 (53%)
Mean disease duration
(CI 95%)
3.3 (2.9,3.6)
Median EDSSc
(minimum, maximum)
4 (1.5, 7)
Mean MSFCd (CI 95%) −1.2 (−0.7, −1.6)
a Conﬁdence interval.
b Non-signiﬁcant.
c Expanded disability status scale.
d Multiple sclerosis functional composite.patients were excluded from this original group to match patients' age
to that of a group of healthy controls (Khaleeli et al., 2007). Subjects
were assessed longitudinally at baseline, and then after 1, 2, 3, and
5years (see Supplementary Table 1 for number of participating subjects
at each time-point). At each time-point, patients were scored on the ex-
panded disability status scale (EDSS) (Kurtzke, 1983), and the multiple
sclerosis functional composite (MSFC) (Cutter et al., 1999), that consists
of timed 25-foot walk test (TWT), paced auditory serial addition test
(PASAT) and the nine hole peg test (NHPT). The study protocol was
approved by Joint Medical Ethics Committee of the National Hospital
for Neurology and Neurosurgery, London. Written informed consent
was obtained from all participants.
Image acquisition
All scans were acquired on a1.5T GE Signa scanner (General Elec-
tric, Co, Milwaukee, Wisconsin). At each time point, all subjects
underwent T1-weighted 3D fast spoiled gradient recalled imaging
(3D-FSPGR) [with 124 contiguous 1.5 mm axial partitions, TR
13.3 ms, TE 4.2 ms, matrix 256 × 256, image in-plane resolution
1.17 × 1.17mm], and spin echo T2-weighted imaging [with 28 con-
tiguous 5 mm thick axial slices, TR 1720 ms, TE 80 ms, matrix
256 × 256, ﬁeld of view (FOV) 240 × 240 mm]. The scanner
underwent a major upgrade during the study. Thirty percent of the
images for healthy controls and 41% of the data for patients were ac-
quired after the scanner upgrade. We adjusted for scanner upgrade
in all statistical analysis presented in this work (see below).
Image analysis
We performed longitudinal VBM following a modiﬁcation of proce-
dures previously implemented in the SPM software (Wellcome Trust
Center for Neuroimaging, UCL, London, www.ﬁl.ion.ucl.ac.uk/spm)
(Chetelat et al., 2005; Kipps et al., 2005).
Brief overview of TBM and longitudinal VBM
TBMand longitudinal VBMare techniques that use precise non-linear
registration over time to determine brain changes; these methods are
more powerful for longitudinal studies of neurodevelopmental and neu-
rodegenerative disorders than classical cross-sectional VBM (Ashburner
and Friston, 2000), which uses segmentation of tissue classes at each
time-point (Anderson et al., 2012). After brain images from different
time-points arematched together, a complete analysis of volumetric dif-
ferences encoded by the spatial transformations can be performed with
TBM. Statistical parametric mapping analysis (SPM) for TBM is most
powerful with smooth images, but smoothing of the Jacobian deter-
minants reduces the effects by cancelling tissue contraction with
neighbouring ventricular expansion. This can be avoided by separating
the expanding and contracting regions (Scahill et al., 2002), but this sep-
aration has the disadvantage that a group difference in the variability of
atrophy could be converted to a (false positive) group difference inmean
atrophy. By multiplying relative volumes by segmented GMmaps, volu-
metric changes related to other regions are discounted, and this product
gives interpretable estimates of the GM volume for the different time-
points. Furthermore, the GM segmentation can be obtained from the
within-subject average of multiple time-points increasing signal-to-
noise ratio and ameliorating artefacts (Chetelat et al., 2005). Such
within-subject processing needs to avoid asymmetries (e.g., towards the
baseline image) that can lead to biases and false positive changes (Fox
et al., 2011; Thomas et al., 2009; Thompson et al., 2011; Yushkevich
et al., 2010). Thereforewe adopted the symmetric approach of registering
all time-points to unbiased within-subject average images (Reuter et al.,
2012; Rohrer et al., 2013).
SPM8, Freesurfer 5.1 (http://surfer.nmr.mgh.harvard.edu/) and FSL
4.1.9 (FMRIB's software library, www.fmrib.ox.ac.uk/fsl) were used for
Fig. 1.Diagram of themain longitudinal VBM steps performed in ﬁrst level analysis (see text for more details). VBM; voxel-basedmorphometry, FSL; FMRIB's Software Library, BET; brain
extraction. DARTEL; Diffeomorphic Anatomical Registration using Exponentiated Lie algebra, GM; grey matter.
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consists of the following main steps (Fig. 1):
1. Lesion mask creation and lesion ﬁlling:
T2 lesions were contoured in Dispimage (Department of Medical
Physics and Bioengineering, UCL, London) and a binary lesion mask
was obtained. T2-weighted images, along with lesion masks, were
co-registered to T1-weighted images using rigid registration
(SPM8) by maximizing the mutual information of the joint intensity
histogram of the images. Lesion masks were used for automatic le-
sion ﬁlling with intensities similar to the normal WM voxels in T1-
weighted images, to avoid lesion-associated segmentation errors
(Sdika and Pelletier, 2009).
2. Brain extraction:
All T1-weighted images were corrected for non-uniformity (Sled
et al., 1998) and non-brain tissue was removed using FSL BET soft-
ware with default BET parameters (Smith, 2002). These images
were then, if required, manually edited.
3. Unbiased within-subject template construction:
To avoid asymmetric treatment of time-points, an unbiased within-
subject average template was constructed from all available time-
points (Reuter and Fischl, 2011; Reuter et al., 2012). The within-
subject average template is a voxel-wise intensity median image
that is more accurate and insensitive to outliers compared to arith-
metic mean templates (Reuter et al., 2010). For template construc-
tion, as the ﬁrst step, a median image was calculated from all time-
points. Using a robust and inverse-consistent registration algorithm,
all available time-points were registered and re-sampled to the me-
dian image (Reuter et al., 2010). A newmedian imagewas computed
iteratively, until transformations obtained from the previous step
converged. This ﬁnal template was used for further processing. This
will be referred to as ‘within-subject template’ throughout this study.4. Deformation ﬁelds and Jacobian determinants:
Following rigid registration of all time-points to their within-subject
template, non-rigid registration was performed using the high-
dimensional warping (HDW) (Ashburner et al., 2000) toolbox in
SPM8 (regularisation parameter of four with 8 iterations). Deforma-
tion ﬁelds that map each time-point to the within-subject template
were obtained, from which Jacobian (tensor) determinant maps
were calculated, showing the contraction or expansion of each
voxel relative to the within-subject template image.
5. Segmentation of within-subject templates:
Within-subject templates were segmented into WM, GM, and CSF
tissue maps using the ‘New Segmentation’ toolbox in SPM8. GM tis-
sue class images were used for the rest of our analysis (Weiskopf
et al., 2011).
6. “Pseudo-time-point segmentations”:
In order to restrict the analysis to GM tissue, GM images fromwithin-
subject template were multiplied voxel-by-voxel with the HDW Ja-
cobian determinant images that show the amount of volume change.
Therefore this step produces images that show the probabilistic vol-
ume of GM at each time-point. These product images will be called
‘pseudo-time-points’ henceforth.
7. Spatial normalisation:
In the next step, GM tissue class images from within-subject tem-
plateswere fed intoDARTEL to create a study-speciﬁc group-wise av-
erage template (Ashburner, 2007). To account for the unbalanced
number of subjects in the patient and control groups, the template
was constructed from a balanced set containing all images from the
control group with only 19 randomly selected images from the pa-
tient group. DARTEL ﬂow ﬁelds that warp each subject to the
study-speciﬁc template were calculated, and then used to normalize
all pseudo-time-point images toMNI spacewithGaussian smoothing
(full width at half maximum 8mm). Since the focus is on thewithin-
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cative noise related to intersubject variability of brain shape, which
is more pronounced in high-resolution normalisation algorithms
(Radua et al., 2014), we chose to proceed without modulation
(Thomas et al., 2009).
Statistical analysis
Summary statistic approach for longitudinal data
Unbalanced serial data (i.e. that with differing numbers of unequally
spaced time-points) preclude the use of standard repeated-measures
ANOVA, whilst voxel-wise imaging data complicate the use of efﬁcient
mixed-effects models (cf. Schott et al., 2010). We therefore employ
the two-level summary-statistic approach (Matthews et al., 1990),
which is similar to the “random-effects” approach commonly employed
for functional imaging studies (Friston et al., 2006), and is relatively ro-
bust to imbalances such as missing time-points (Mumford and Nichols,
2009).
Rate of disability and WM lesion load progression in patients
First, changes in EDSS score were converted to EDSS-steps as de-
scribed elsewhere (Wingerchuk et al., 1997). In order to identify the an-
nual rates of change in clinical scores, the slopes of linear regressions
against time for EDSS and MSFC were calculated using least-squares. A
similar approachwas used to calculate the rate ofWM lesion load accru-
al over time. To test whether patients had signiﬁcant disability progres-
sion, a one-sample t-test was utilized to compare the slope of EDSS and
MSFC against the null hypothesis of no progression over time.
Temporal and spatial evolution of GM volume loss
For each subject, the slope of a ﬁrst-level least-squares linear regres-
sion against time was computed at each voxel, using all available time-
points; this slope image shows the (linear) rate of volume change over
time in each voxel. The slope summary-statistic images for all subjects
were then taken to the second level for between-subject analysis to in-
vestigate dynamic GM changes in both the patient and control groups,
and the group difference in atrophy rates. An unbiased explicit GM
mask from GM probability maps of the smoothed within-subject tem-
plates in MNI space was created for second-level analysis, as described
elsewhere (Ridgway et al., 2009). A two-sample t-test was used to com-
pare the rates of atrophy between patients and controls. All the above
statistical models were adjusted for age, gender and total grey matter
volume at baseline as nuisance covariates in the second level model.
In addition the proportion of images that were acquired after scanner-
upgradewas obtained for each subject andmodelled as nuisance covar-
iate in the second level.
To test whether therewas an acceleration or deceleration in the rate
of GM volume change over time, the quadratic term from a second-
degree polynomial regression against time was calculated for each sub-
ject and submitted to second-level between-subject analysis.
Results were corrected for multiple comparisons using threshold-
free cluster enhancement (TFCE) (p FWE b 0.05 with 5000 permuta-
tions) as implemented in FSL randomise (Smith and Nichols, 2009).
Post-hoc analysis of year-by-year volume loss in patients without missing
time-points
To describe the changes in volume occurring year by year, we
subtracted GM probability at each time-point from that of baseline in
15 patients who attended all the follow-up visits. The difference images
were then fed into FSL randomise and one sample t-test was performed
(5000 permutations). Results were corrected for multiple comparisons
across space using voxel-wise FWE (pb0.05) (without TFCE).
Relationship between volume changes and clinical ﬁndings
To investigate the relationship between GM volume changes and
progression of disability, we correlated the slopes of EDSS, MSFC andT2 lesion-load that represent the annual rates of change, with the GM
volume slope images. Additionally, to assess the association between
the GM volume loss rate and long-term clinical outcome, a correlation
analysis was performed between the rate of GM volume loss and EDSS
and MSFC at 5 years. Also, a partial correlation analysis between the
rate of GMvolume decline andMSFC at 5years, adjusting for normalized
GM volume (SIENAX FSL 4.1.9, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/
SIENA), was performed to test whether the association between atro-
phy rate and disability at the end of the study holds after accounting
for baseline differences of pathology.
Results
Rate of disability and WM lesion load progression in patients
Patients progressed during the ﬁve-year follow-up, with a mean de-
crease of 0.25±0.39 (mean±standard deviation) in MSFC per annum
(pb0.001), and amean increase of 0.36±0.71 in EDSS per annum (p=
0.01). There was a mean increase of 2.59±3.41ml per annum in WM
lesion load.
Temporal and spatial evolution of GM volume loss
The rate of volume loss was not uniform across the brain, but affect-
ed different GM structures with variable rates (as shown in Fig. 2); it
appeared to be the fastest in the bilateral cingulate gyri and the slowest
in the pre-central gyrus. Patients showed a greater rate of reduction in
GM volume in the bilateral cingulate gyri and the adjacent precuneus,
the cerebellum, the bilateral precentral gyri, the bilateral thalami, and
the insula, in comparison with healthy controls over the ﬁve-year peri-
od (Table 2 and Fig. 3) (p FWEb0.05, TFCE). Therewas no signiﬁcant ac-
celeration or deceleration in GM volume change (i.e., change in the rate
of atrophy over time) in patients or controls (analogous to one-sample
t-tests on the quadratic terms), and no signiﬁcant group difference be-
tween patients and controls (analogous to a two-sample t-test on the
quadratic terms).
Post-hoc analyses of year-by-year volume loss in patients without missing
time-points
In patients, there was no signiﬁcant volume loss at ﬁrst and second
year when compared to baseline. A signiﬁcant volume loss in the left
insula, left precuneus, and right cingulate cortex was detected at three
years, whilst the bilateral putamen and the left superior temporal
gyrus showed volume loss subsequently, at ﬁve years (see Table 3 for
further details).
Relationship between volume changes and clinical ﬁndings
In patients, a greater rate of volume loss in the bilateral cingulate
gyrus was associated with worse MSFC at 5 years (r = 0.49, p =
0.003), (Fig. 4). In addition, this association persisted after correction
for baseline normalized GM volume (r=0.51, p=0.001).
There was no signiﬁcant association between the rate of GM volume
loss and the rate of EDSS step-change, MSFC change, EDSS at 5years and
rate of T2 lesion load accrual per annum.
Discussion
The four key ﬁndings of this study were (i) there was a marked pro-
gression of atrophy in several GM regions in patientswhen compared to
healthy controls; (ii) the progression of GM atrophy in patients occurs
at different rates in different regions across the brain; the fastest atro-
phy is seen in the cingulate cortex and the slowest in the precentral
gyrus; (iii) some regions showed a signiﬁcant volume loss at a later
time point than other regions; (iv) there was a signiﬁcant association
Fig. 2. Linear rate of GM volume reduction in patients (A) and in healthy controls (B) adjusted for age, gender, total grey matter volume and the scanner upgrade. Bottom row:
Unthresholded one-tailed t-statistic map for negative linear effect of time adjusted for nuisance covariates (see above) in patients with PPMS (C) and healthy controls (D). The posterior
cingulate gyri and adjacent precuneus (arrows) show the highest rate of volume loss in the patient group. PPMS; primary progressive multiple sclerosis, HC; Healthy controls.
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outcome at ﬁve years. We will discuss these results in turn.
The ﬁndings of including the bilateral cingulate gyri with the adja-
cent precuneus, cerebellum, bilateral precentral gyri, and bilateral thal-
ami, and insula, are broadly consistent with our cross-sectional and
longitudinal studies in the same cohort (Ingle et al., 2005; Khaleeli
et al., 2007, 2008; Sastre-Garriga et al., 2005; Sepulcre et al., 2006) and
with previous studies from different centres in other types of MS
(Audoin et al., 2010; Battaglini et al., 2009; Bendfeldt et al., 2012;
Ceccarelli et al., 2008; Fisher et al., 2008). However, we used for theTable 2
Regions that show a statistically signiﬁcant greater rate of GM atrophy in patients than in cont
Peak location pFWE t-Value Clu
Anterior cingulate gyrus 0.004 4.87 14,
Left thalamus 0.009 5.34 2
Left putamen 0.031 4.59
Right precentral gyrus 0.041 3.61
Left precentral gyrus 0.046 3.11
Right insula 0.035 5.33
Corrected for multiple comparisons across space with p FWE b 0.05, threshold-free cluster enhﬁrst time an unbiased and novel longitudinal VBM approach, which is
more precise than standard methods of analysis of volume changes.
Themost interesting ﬁnding of our study is that the volume loss ob-
served in the regions mentioned above did not occur at the same speed
throughout the brain, but involved different regionswith variable rates.
The highest speed of GMvolume losswas seen in the cingulate gyri with
adjacent precuneus. This region showed a signiﬁcant atrophy in patients
at 3years when compared with baseline, and the rate of volume loss of
this region was greater in patients with higher neurological disability at
5 years. Distinctive GM atrophy in the cingulate cortex of early PPMSrols.
ster size (voxels) Peak MNI coordinates (mm)
X Y Z
919 7.5 16.5 30
272 −7.5 −31.5 1.5
351 −19.5 3 −3
305 22.5 −22.5 69
181 −9 −19.5 63
77 31.5 9 −3
ancement.
Fig. 3. Signiﬁcant regions of annualized GM loss over 5 years (most informative slices are
shown). Two-sample t-test shows signiﬁcantly greater rate of atrophy in the cingulate cor-
tex, precentral gyrus, thalamus, cerebellum, and insula in the patients as compared to con-
trols. Coordinates are in MNI space. Results are adjusted for age, gender and scanner-
upgrade and corrected for multiple comparisons across space with p FWE b 0.05,
threshold-free cluster enhancement. FWE; Family-Wise Error.
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(Geurts andBarkhof, 2008). Posteriormedial cortical structures (includ-
ing the posterior cingulate cortex and the ventral precuneus) are among
the most metabolically active regions that are part of the default mode
network (DMN) of the brain (Raichle et al., 2001; Zhang and Raichle,
2010). The DMN supports internally directed mental activity and plays
an important role in the regulation of cognitive functioning (Nakano
et al., 2013). The DMN shows connectivity changes from early stages
in MS (Roosendaal et al., 2010), but whether it has a compensatory or
maladaptive role has not yet been clariﬁed. A high metabolic rate
alongwith an increased demand for energy to repair axonal and cellular
damage following demyelination, and a decreased energy supply sec-
ondary to mitochondrial dysfunction with consequent reduction in
ATPproduction from respiratory chains (Lassmann et al., 2012),may in-
duce a chronic state of virtual hypoxia (Trapp and Stys, 2009) with a
subsequent axonal vulnerability. Additionally, the cingulate region, es-
pecially in its anterior portion, is known to contribute to motor control,
via its connections with the spinal cord and motor cortex; therefore, a
higher rate of atrophy of this region may be expected to lead to greater
physical and cognitive disability, as assessed by the MSFC, at 5 years.
However, there was no correlation between the rate of GM volume re-
duction and the rate of MSFC change; this can be explained by the com-
plex relationship between functional and structural changes in MS
(Tomassini et al., 2012) and by the role played by the GM lesions
(Calabrese et al., 2013),whichwere not included in our study. Addition-
ally, Fig. 4 shows that somepatientsweremore disabled than others de-
spite having the same rate of atrophy; this suggests that there may be
factors that contribute to the disability in addition to GM atrophy,
such as spinal cord damage, which are not investigated in this study,Table 3
Post-hoc analysis of GM volume loss at different stages of early PPMS.
Peak location pFWE t-Value
Year 3 vs. baseline
Left insula 0.005 5.6
Left precuneus 0.004 5.68
Right cingulate gyrus 0.018 5.19
Year 5 vs. baseline
Left putamen 0.001 6.47
Superior temporal lobe/left insula 0.003 5.83
Right putamen 0.004 5.7
Right cingulate gyrus 0.003 5.86
Left precuneus 0.019 5.2
Corrected for multiple comparisons across space with p FWE b 0.05 at voxel level.and that clinical scores may have a limited ability to reﬂect the real ex-
tent of neurological disability (Barkhof, 2002).
Our previous cross-sectional VBM analysis in the same patient cohort
has shown volume changes in the pre-central cortex and thalamus in pa-
tients with PPMS when compared to healthy controls (Khaleeli et al.,
2007). We have extended this observation by demonstrating that the
progression of atrophy continues in these regions in patients over
5 years. Preferential involvement of the particularly long projections
from pyramidal neurons can account for axonal and neuronal loss in
the pre-central gyrus (Narayanan et al., 1997), although this region
showed the slowest progression of atrophy. This may be explained by
B-cell follicle-like structures (which are harbinger of meningeal inﬂam-
mation and subsequent tissue loss) that could be frequently found in
the deep sulci of the forebrain (cingulate, temporal and insular areas)
in people suffering from SPMS (Howell et al., 2011). Also, we found a
concurrence between regions with higher metabolism and higher rate
of atrophy and postulated that this might be attributed to energy failure
andmitochondrial dysfunction inMS (see above).Most of these could be
found in regions affected by progressive atrophy — areas other than the
precentral gyrus (e.g. cingulate cortex, insula, thalamus). A wealth of ev-
idence implicates particular vulnerability of deep GM structures (mainly
the thalamus) in MS (Lassmann et al., 2012; Sepulcre et al., 2006). Thal-
ami act as the hub of important brain networks (highly interconnected
with a plethora of cortical regions), subserving a spectrum of functions
ranging from motor to cognition and consciousness (van den Heuvel
and Sporns, 2011). This inevitably renders the thalamus vulnerable to
diffuse MS-associated pathological processes (Minagar et al., 2013).
A signiﬁcant progression of atrophy over 5years was seen in patients
in the cerebellum. The cerebellum is a major predilection site for demy-
elination especially in progressive subtypes of MS that usually escapes
detection by conventional MRI studies (Kutzelnigg et al., 2007). Indeed,
the deepmeningeal infoldings in the cerebellum could accommodate in-
ﬂammatory processes for a prolongedperiod of time,which could lead to
the ﬁnal occurrence of atrophy in the cerebellar cortex. Our post-hoc
model performed on a subset of 15 patients with no missing data did
not show GM loss in the cerebellum, but this might simply reﬂect re-
duced statistical power in comparison with the two-level summary sta-
tistics approach that included all available time-points for all subjects.
An interesting observation of our study is that signiﬁcant atrophy in
the putamen bilaterally and in the left superior temporal gyrus is ob-
served at year 5 when compared to baseline, which is at a later time
point compared with the volume loss occurring in other regions, such
as the cingulate cortex, the insula and the precuneus. Subpial demyelin-
ation affects areas with restricted cerebrospinal ﬂuid circulation that
can explain earlier GM volume reduction in the cingulate and insular
cortices that we found in this cohort, suggesting an effect from stagnant
mediators of adjacent meningeal inﬂammation (Kutzelnigg et al.,
2007). Moreover, the cingulate cortex, insula and the temporal lobe
have been shown to have the most frequent cortical lesions (Bo et al.,
2003; Vercellino et al., 2005). Insular atrophy was more pronouncedCluster size (voxels) Peak MNI coordinates (mm)
X Y Z
100 −43.5 −36 15
72 −13.5 −60 12
49 10.5 −45 36
165 −19.5 9 −6
152 −51 −40.5 21
102 22.5 15 −4.5
100 10.5 −45 36
22 −13.5 −61.5 13.5
Fig. 4. Scatterplot and trend line showing the association between the rate of volume loss
in posterior cingulate cortex (AAL atlas) and MSFC at 5 years (r= 0.49, p=0.003). More
negative values on X-axis represent higher rate of volume loss. MSFC scores are Box–Cox
transformed with a shift parameter of 10 to improve normality. Two outliers have been
excluded from the analysis (Pearson's r = 0.53, p b 0.001 without excluding outliers).
The correlation holds after correction for baseline GM normalized volume (Pearson's
r=0.51, p=0001). AAL; Automatic Anatomical Labeling.
263A. Eshaghi et al. / NeuroImage 86 (2014) 257–264in its posterior section, which is more densely myelinated and have
prominent connections to the premotor cortex, superior parietal lobule
(precuneus) and cingulate regions (Flynn, 1999). These results show
that how future connectomic researchmayplay a role to further our un-
derstanding of the pathological substrates of neurodegeneration in MS
(Griffa et al., 2013).
When looking at the temporal and spatial progression of atrophy in
other neurodegenerative and neuropsychiatric disorders a similar pic-
ture of accelerated GM loss may emerge: the cingulate cortex and tem-
poral lobe in persons with Alzheimer's and Parkinson's disease
(Chetelat et al., 2005; Ramirez-Ruiz et al., 2005), subcortical structures
such as thalamus in individuals with Huntington's disease and
frontotemporal dementia (Hobbs et al., 2010; Mahoney et al., 2012),
and superior temporal lobe in persons with schizophrenia (Vita et al.,
2012). Higher involvement of certain regions over time strengthens
the hypothesis of a speciﬁc relevance of these regions in the pathophys-
iology of each disorder. Overall, our results may suggest that similar to
other neurodegenerative and neuropsychiatric disorders, atrophy is
more pronounced in speciﬁc regions of the brain in people with PPMS
and may progress chronologically so that the cingulate cortex and the
precuneus are affected earlier than the putamen, although the number
of patients attending all ﬁve time points was small.
A methodological consideration is that we used registration-based
pseudo-time-points, which tend to underestimate biological changes,
and are more computationally expensive compared to the separate seg-
mentation and subtraction of the time-points. However, our method
provides a lower variance for estimation of the atrophy rate, is less sus-
ceptible to segmentation errors, and is more statistically powerful than
separate segmentation of time-points (Anderson et al., 2012). Addition-
ally, we utilized a symmetric approach of registering to a median inten-
sity image as a template to reduce bias related to asymmetry, as well as
the effects of outliers (e.g., due tomovement), which is an important im-
provement in comparison with previous works. Future research could
further improve longitudinal VBM and TBM methods (Ashburner and
Ridgway, 2012). Another limitation common to all voxel-basedmethods
(including SPM, VBM and TBM) is that differences between regions are
not formally tested for signiﬁcance (Jernigan et al., 2003). This means
that apparent regional differences should be interpreted cautiously, par-
ticularly with regard to non-signiﬁcant regions, since sensitivity varies
across the brain due to variation in the accuracy of registration and seg-
mentation (Pereira et al., 2010; Ridgway et al., 2008). It should also benoted that summary-statistics approach to mixed-effects modelling is
most effective for highly structured data (i.e., similar observations for
all subjects).Moreover, realmixed-effectmodelsmight improve the sen-
sitivity of the second level inference by accounting for the variable
precision of within-subject measurements. Finally, since non-linear reg-
istration algorithms are inherently less stable than linear registration al-
gorithms a possible adjunct for future studies is to impose a penalty term
inhigh dimensionalwarping related to the proximity and quantity of GM
lesions seen on more sensitive MR sequences (e.g. DIR).
In conclusion, using a novel longitudinal VBM approach we demon-
strated that the rate of GM atrophy in early PPMS is not identical
throughout the brain. This is relevant for the development of imaging
outcome measures in neuroprotective clinical trials, which commonly
employ total GM and whole brain atrophy. Regions characterised by a
particularly active metabolism, higher interconnection with other
brain regions, and possibly affected by overlying meningeal inﬂamma-
tion, such as the cingulate cortex, may be particularly vulnerable to at-
rophy and their volume loss may be associated with clinical outcome.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2013.09.059.Acknowledgments
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